** Shares of California-based drug developer Ideaya BiosciencesIDYA.O down 4.5% at $16.28
** IDYA receives breakthrough therapy designation for company's experimental drug, darovasertib, to treat a type of eye cancer called neoadjuvant uveal melanoma, before surgery
** Brokerage Leerink Partners says the majority of the neoadjuvant opportunity lies in the ~80% of patients scheduled for radiotherapy (both plaque and beam), which does not appear to be included in this designation
** "The drug will likely need to show an improvement over placebo in time" - Leerink Partners
** IDYA says the drug is currently being tested in a mid-stage trial and co plans to begin a late-stage study in H1 2025
** Neoadjuvant Uveal Melanoma affects 12,000 patients annually and is a high unmet medical need with no FDA-approved systemic therapies - IDYA
** Stock had fallen 35.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.